Epilepsy & Seizures

Filter Your Results

 

News

 

Sunovion Submits NDA to Expand Aptiom Indication to Pediatric Patients

Tuesday, March 14, 2017—Sunovion Pharmaceuticals has submitted a supplemental new drug application (sNDA) to the FDA to expand the indication for its antiepileptic drug AED Aptiom (eslicarbazepine ac…

Takeda and Ovid Strike Partnership to Develop Investigational Agent for Rare Pediatric Epilepsy

Thursday, January 19, 2017—Takeda and Ovid Therapeutics are teaming up for the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel CH24H inhibitor, in …

NeuroPace Unveils New Long-Term Data for Its RNS System

Friday, December 09, 2016—At the recent American Epilepsy Society Annual Meeting in Houston, NeuroPace shared new long-term data for its RNS System for the treatment of partial-onset seizure. The RNS S…

Reflecting on New Phase 3 Epidiolex Data, GW Pharmaceuticals CEO Emphasizes Education About Cannabidiol

Thursday, December 08, 2016—Greenwich Biosciences, a subsidiary of GW Pharmaceuticals, shared phase 3 data in poster presentations at the recent American Epilepsy Society Annual Meeting showing that it&r…

AES 2016: Fenfluramine Found Effective for both Dravet Syndrome and LGS

Wednesday, December 07, 2016—New poster data from Zogenix presented at the recent American Epilepsy Society’s annual meeting in Houston paints an encouraging portrait of the company’s investig…

AES 2016: Sunovion Launching Phase 4 Study of Aptiom Using Wearable Technology to Detect Seizure Activity

Wednesday, December 07, 2016—At the recent American Epilepsy Society Annual Meeting in Houston, Sunovion revealed that will soon initiate enrollment for a Phase 4 clinical study (Study 093-701) evaluating…

Adjunctive Treatment with Lyrica Found to Reduce Seizure Frequency in Pediatric Epilepsy

Thursday, December 01, 2016—New phase 3 results show that Lyrica (pregabalin, Pfizer) Capsules CV is an effective adjunctive therapy for patients with epilepsy between the ages of four and 16 years of ag…

Phase 1 Data Show Rapid Absorption of Intranasal Midazolam in Pediatric Patients with Epilepsy

Friday, October 28, 2016—New Phase 1 data show that intranasal midazolam spray (USL261, Upsher-Smith) in pediatric participants with epilepsy is rapidly absorbed and with no dose-dependent no differen…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC